%D8%B3%D9%8A%D8%AA%D9%88%D9%83%D8%B3%D9%8A%D9%85%D8%A7%D8%A8%D8%B3%DB%8C%D8%AA%D9%88%D8%B3%DB%8C%D8%A7%D9%85%D8%A8Category:CetuximabCetuximab%CE%9A%CE%B5%CF%84%CE%BF%CF%85%CE%BE%CE%B9%CE%BC%CE%AC%CE%BC%CF%80%CE%B7CetuximabCetuximabTsetuksimaab%D8%B3%D8%AA%D9%88%DA%A9%D8%B3%DB%8C%E2%80%8C%D9%85%D8%A8C%C3%A9tuximab%D7%90%D7%A8%D7%91%D7%99%D7%98%D7%95%D7%A7%D7%A1CetuximabCetuximab%E3%82%BB%E3%83%84%E3%82%AD%E3%82%B7%E3%83%9E%E3%83%96CetuksymabCetuximab%D0%A6%D0%B5%D1%82%D1%83%D0%BA%D1%81%D0%B8%D0%BC%D0%B0%D0%B1CetuksimabCetuksimabCetuksimab%D0%A6%D0%B5%D1%82%D1%83%D0%BA%D1%81%D0%B8%D0%BC%D0%B0%D0%B1Q420296%E8%A5%BF%E5%A6%A5%E6%98%94%E5%96%AE%E6%8A%97
about
sameAs
BRAF V600ECDKN2A p16 EXPRESSIONKRAS EXON 2 MUTATIONERBB2 AMPLIFICATIONKRAS G12/G13KRAS G12DKRAS G13DNRAS Q61PIK3CA E542KPIK3CA E545KPIK3CA EXON 21 MUTATIONPIK3CA H1047RKRAS G12AKRAS G12VEGFR G465REGFR S492REGFR K467TKRAS G12RBRAF D594GNRAS MUTATIONPTEN LOSSSMAD4 MUTATIONFBXW7 MUTATIONSMAD4 UNDEREXPRESSIONERBB3 OVEREXPRESSIONPIK3CA MUTATIONNRG1 EXPRESSIONKRAS MUTATIONEGF EXPRESSIONBRAF MUTATIONVPS37A UNDEREXPRESSIONKRAS A146PKRAS A146TKRAS G12SKRAS G13VPIK3CA V955I
P3355
P3781
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction DesignAvelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable CancerDoxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade GliomasSULTAN (Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network)Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By SurgeryStudy of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial CancerCetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal CancerCombination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal CancerEfficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) ExpressionsStudy of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First TherapyRandomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast CancerA Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)Radiotherapy, Cetuximab, and Injections of TNFeradeā¢ Biologic for Elderly or Frail Patients With Head and Neck CancerA Study of the Perioperative Use of Cetuximab in Colon Cancer PatientsStudy of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLCRetrospective Study Assessing Molecular Features Predicting Response to CetuximabCetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal CancerA Trial of Chemo & Radiation Therapy for Pancreatic CancerSafety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal CancerCetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerEfficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before ProstatectomyCetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal CancerS0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung CancerEMMA-1 (Erbitux for Multiple Myeloma)Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast CancerTopical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for CancerA Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal CarcinomaChemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)Study in Advanced Solid TumorsNeo-Adjuvant Study in Triple Negative Breast Cancer PatientsInvestigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced FolliculitisA Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and NeckProspective, Post Marketing Surveillance Study On ErbituxĀ® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in KoreaARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerAn Observational Study of ErbituxĀ® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing TreatmentPrognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.Study of ABT-700 in Subjects With Advanced Solid TumorsCetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by SurgeryInduction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck CancerBiomarkers in Patients With Head and Neck Cancer
P4844
Afatinib / Cetuximab combination therapyCetuximab / Sirolimus combination therapyErlotinib / Cetuximab combination therapyVemurafenib / Gefitinib / Cetuximab combination therapyPanitumumab / Cetuximab combination therapyIrinotecan / Vemurafenib / Cetuximab combination therapyCetuximab / vemurafenib combination therapydocetaxel trihydrate / Cetuximab combination therapydasatinib monohydrate / Cetuximab combination therapyCetuximab / encorafenib combination therapydactolisib / Cetuximab combination therapyCetuximab / platinum / fluorouracil combination therapycrizotinib / Cetuximab combination therapyCetuximab / capecitabine / Oxaliplatin combination therapyCetuximab / selumetinib combination therapyFOLFOX-4 / Cetuximab combination therapyirinotecan / Cetuximab combination therapycetuximab / chemotherapy combination therapy
P527
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewComplement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivoChemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancerChemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancerCetuximab/C225-induced intracellular trafficking of epidermal growth factor receptorActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabRandomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancerA Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal CancerCetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier?The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after firEGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysisCetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck CancerPhase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.Cetuximab for the treatment of colorectal cancer.KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.K-ras mutations and benefit from cetuximab in advanced colorectal cancer.Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximabAssociation of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.
P921
Q11613500-80E2535D-8142-42A8-8610-FD9731D48922Q1393463-EF956FB6-3C62-490F-9A03-1FD5FF97A42FQ18348812-AC3DB8A1-B035-4B1C-B5DA-7F760A1C459CQ18554959-5A978A03-EA5F-4693-945C-E950A320062CQ18555025-6A3E9648-4677-4F2D-8355-0360CA67F397Q18555055-A5E69585-DDBB-46BA-A015-287C770101EAQ18557977-502FE71C-DC21-404E-9A44-4F1BB40AD2BAQ18558027-2F3B0BD2-AEB8-473C-9B11-BBC7C3FD7065Q2031424-01B1019C-B878-4BCC-9180-7B27DA5EE044Q2739660-026AE9DD-CB27-48B8-898B-5669A8555D7BQ28757362-75744437-6A2D-4FBA-89E6-5ED4B322FCA4Q3658562-EE21BE5C-A17A-45E6-A14D-E0584517D5CFQ5749018-2B570353-242B-405F-8F1E-4429F1CA9146Q852423-17879910-665B-4B15-B913-702B6FDEAEA6
P2176
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemickĆ” slouÄenina
@cs
chemickĆ” zlĆŗÄenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Cetuksimab
@sh
Cetuksimab
@sl
Cetuksimab
@sr
Cetuximab
@de
Cetuximab
@es
Cetuximab
@hu
Cetuximab
@it
Cetuximab
@nl
Cetuximab
@pt
Tsetuksimaab
@et
type
label
Cetuksimab
@sh
Cetuksimab
@sl
Cetuksimab
@sr
Cetuximab
@de
Cetuximab
@es
Cetuximab
@hu
Cetuximab
@it
Cetuximab
@nl
Cetuximab
@pt
Tsetuksimaab
@et
altLabel
205923-56-4
@fr
Anti EGFR
@en
C225
@en
C225
@ja
C6484H10042N1732O2023S36
@fr
C6484H10042N1732O2023S36
@it
Cetuximab
@he
Cetuximab
@zh
Erbitux
@de
Erbitux
@en
prefLabel
Cetuksimab
@sh
Cetuksimab
@sl
Cetuksimab
@sr
Cetuximab
@de
Cetuximab
@es
Cetuximab
@hu
Cetuximab
@it
Cetuximab
@nl
Cetuximab
@pt
Tsetuksimaab
@et
P2175
P31
P486
P592
P6366
P646
P665
P117
P1705
Cetuximab
@und
P2115
N0000148833
P2175
P2275
cetuximab
@en
P231
205923-56-4
P267
P3117
DTXSID0040830
P3345
P373
P3780
P486
D000068818
P592
CHEMBL1201577